In recent years, circulating tumor DNA (ctDNA) for the detection of molecular residual disease (MRD) and treatment response monitoring in solid tumors has been increasingly incorporated into clinical practice and trials.
This growing utilization has created a unique opportunity to amass and interrogate a longitudinal real-world clinico-genomics dataset of early and late-stage cancer patients, with the potential to provide drug developers and researchers with a more granular understanding of tumor biology and signals of therapy response.
In this webinar, we will discuss use cases for such a dataset and how it can support the optimization and acceleration of clinical development
Dr. Alexey Aleshin, MD, MBA, has led the oncology clinical development efforts at Natera, Inc. since 2018. Prior to this, he worked on the various novel ctDNA technologies while at Stanford University. He remains a clinical adjunct faculty in the division of Hematology at Stanford, where his work focuses on novel diagnostics assays for treatment decision support in hematologic malignancies. He received a B.A. in Statistics from UC Berkeley and his M.D./M.B.A. degrees at UCLA. He completed his clinical training in internal medicine and hematology/oncology at Stanford University.
As Chief Technology Officer at Natera, Rishi is leading efforts to establish a new clinico-genomics data platform across oncology and organ health/rare disease. Prior to Natera, he was the Chief Technology Officer at Myriad Genetics and the Cofounder, SVP of Product, and VP of Engineering at Counsyl. Rishi received his B.S. in Computer Science from Stanford University.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.